Ilona Kryczek, PhD
Surgery
109 Zina Pitcher Pl
Ann Arbor, Michigan 48109
Manage Your Profile
About
Dr. Ilona Kryczek is an Associate Research Scientist in the Department of Surgery at the University of Michigan Medical School. An internationally recognized immunologist, Dr. Kryczek’s research focuses on the interplay between the immune system and cancer, with special emphasis on the development of novel immunotherapies for advanced cancers. Her pioneering work explores how immune cells and the tumor microenvironment affect cancer progression, metastasis, and resistance to treatment. Dr. Kryczek’s work has led to over 120 publications in high-impact journals, with more than 34,000 citations, underscoring its substantial influence and recognition within the scientific community. Dr. Kryczek is deeply involved in mentoring the next generation of scientists and is widely sought after as a reviewer and program advisor for leading international funding agencies and journals. Her contributions have been recognized with numerous awards.
Links
https://scholar.google.com/citations?hl=en&user=Rhdk_K4AAAAJ
Qualifications
-
Post-Doctoral FellowTulane School of Medicine, New Orleans, United States
2004 - 2006
Postdoctoral Fellowship
-
Research FellowInserm, Paris, France
2002 - 2003
Postdoctoral Fellowship
-
PhDL. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
1995 - 2000
-
MSUniversity of Wroclaw, Wroclaw, Poland
1990 - 1994
Research Overview
Tumor immunology; regulatory T cells and immune evasion; Th17/Treg balance; stem-like memory T cells; cytokine regulation of cancer stemness; IL-17/IL-22 signaling; tumor immunometabolism; immune checkpoint biology; antigen-presenting cell function; ferroptosis and metabolic regulation of anti-tumor immunity; mechanisms of resistance to cancer immunotherapy; translational immuno-oncology; biomarker discovery and personalized immunotherapy.
Recent Publications
-
Zakharia Y, Singer EA, Acharyya S, Garje R, Joshi M, Peace D, Baladandayuthapani V, Majumdar A, Li X, Lalancette C, Kryczek I, Zou W, Alva A. Nature Communications, 2024 Dec 1; 15 (1):Journal ArticleDurvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043
DOI:10.1038/s41467-024-45216-z PMID: 38302476 -
Choi JE, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, Tien J, Maj T, Yazdani S, Parolia A, Xia H, Zhou J, Wei S, Grove S, Vatan L, Lin H, Li G, Zheng Y, Zhang Y, Cao X, Su F, Rui W, He T, Gondal M, Cieslik M, Green M, Zou W, Chinnaiyan A. bioRxiv, 2023 Jun 29;Journal ArticlePIKfyve controls dendritic cell function and tumor immunity
DOI:10.1038/s41467-024-48931-9 -
Pitter MR, Kryczek I, Zhang H, Nagarsheth N, Xia H, Wu Z, Tian Y, Okla K, Liao P, Wang W, Zhou J, Li G, Lin H, Vatan L, Grove S, Wei S, Li Y, Zou W. Cell Reports, 2024 Mar 26; 43 (3):Journal ArticlePAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages
DOI:10.1016/j.celrep.2024.113942 PMID: 38489266 -
Lo BC, Kryczek I, Yu J, Vatan L, Caruso R, Matsumoto M, Sato Y, Shaw MH, Inohara N, Xie Y, Lei YL, Zou W, Núñez G. Science, 2024 Jan 1; 383 (6678): 62 - 70.Journal ArticleMicrobiota-dependent activation of CD4+ T cells induces CTLA-4 blockade–associated colitis via Fcg receptors
DOI:10.1126/science.adh8342 PMID: 38175892 -
Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen SG, Sankar K, Fecher LA, Mendiratta-Lala M, Frankel TL, Qin A, Waninger JJ, Tezel A, Alva A, Lao CD, Ramnath N, Cieslik M, Harms PW, Green MD, Chinnaiyan AM, Zou W. Cancer Cell, 2023 Feb 13; 41 (2): 304 - 322.e7.Journal ArticleIntersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
DOI:10.1016/j.ccell.2022.12.008 PMID: 36638784 -
Kryczek I. 2026 Mar 3;PresentationTumor Immunology: Immune Checkpoints, Cell Death Mechanisms and Metabolic Pathways
-
Kryczek I. 2026 Mar 3;PresentationTumor Immunology: Immune Checkpoints, Cell Death Mechanisms and Metabolic Pathways
-
Kryczek I. 2026 Mar 3;PresentationBreakthroughs in Tumor Immunology: Immune Checkpoints, Cell Death Mechanisms and Metabolic Pathways